Exo Imaging and Samsung Medison Collaborate on Advanced Ultrasound Solutions and Welcome Omar Ishrak to Board

Exo Imaging, a leading innovator in ultrasound medical imaging technology, announced a strategic collaboration with Samsung Medison to co-develop advanced ultrasound solutions. The partnership includes a strategic equity investment by Samsung, aimed at accelerating the development of next-generation ultrasound platforms. Exo also welcomed Omar Ishrak to its Board as Chair of Strategy. The collaboration reflects a shared vision between Exo and Samsung Medison to drive global advancement in ultrasound through large-scale innovation and strategic co-development.

Exo Imaging, a pioneer in ultrasound medical imaging technology, has announced a strategic collaboration with Samsung Medison to co-develop advanced ultrasound solutions. The partnership includes a significant equity investment by Samsung, aimed at accelerating the development of next-generation ultrasound platforms. Exo also welcomed Omar Ishrak to its Board as Chair of Strategy. This collaboration reflects a shared vision between Exo and Samsung Medison to drive global advancement in ultrasound through large-scale innovation and strategic co-development.

The investment, led by Sands Capital, Bold Capital, and Qubit Health Capital, could total about $100 million [1]. Qubit Health's chairman, Omar Ishrak, a former Medtronic CEO, will join Exo's board as part of the deal. Exo's handheld ultrasound devices and imaging software are designed to improve diagnostic capabilities at the point of care. The company has raised over $320 million in investments from prominent venture capitalists, including RA Capital Management, BlackRock, Intel Capital, Sony Innovation Fund, and Avidity Partners [2].

Exo's primary offering, Exo Iris, is a compact, high-efficiency ultrasound machine that combines curved, linear, and phased array capabilities in a single probe. The device facilitates the application of solutions in numerous clinical settings due to its convenience and ease of use. Additionally, Exo's SweepAI platform, an artificial intelligence system with FDA clearance, provides real-time scanning insights and assists in diagnosing conditions such as heart failure, valvular disease, pneumonia, and pulmonary embolism [2].

The collaboration between Exo and Samsung Medison could create substantial synergies. Samsung Medison, a Samsung subsidiary, specializes in digital X-ray technologies and ultrasound diagnostics. The combination of Exo's advanced imaging technology and Samsung Medison's production capacity and distribution networks could enhance the global reach of Exo's products. This partnership could also improve Exo's footing for many international activities, with a particular focus on telehealth and hospitals [2].

This strategic collaboration underscores Samsung's commitment to enhancing its visibility in the digital health area. Exo could benefit from such funding and strategic support, assisting it in obtaining regulatory approvals faster and advancing its AI product development for market entry. The partnership reflects a shared vision of driving global advancement in ultrasound technology through large-scale innovation and strategic co-development [2].

References:
[1] https://techcrunch.com/2025/05/27/samsung-may-invest-in-100m-round-for-medical-imaging-startup-exo/
[2] https://www.techi.com/samsung-to-invest-100m-in-ai-ultrasound-startup-exo/